(2019)
Thrombotische Mikroangiopathie: Was gibt es Neues?
Der Nephrologe 14(1),
26-31.
(Review)
Prof. Dr. Peter F. Zipfel
Infection Biology · Head International Leibniz Research School · Speaker +49 3641 532-1301 peter.zipfel@leibniz-hki.deCurriculum vitae
Main Research Areas
- Immune escape of human pathogenic micro-organisms
- Infection-associated function of the complement system
- Genetic susceptibility for infections
Professional Career
| Since 2000 | Professor for infection biology, Friedrich-Schiller-University Jena (FSU Jena) |
| Since 2000 | Head of the department infection biology, Leibniz-Institute for Natural Product Research and Infection Biology – Hans-Knöll-Institute Jena |
| 1999 | Nontenured professor, University Hamburg |
| 1993 | Habilitation in immunology and molecular biology, University Hamburg |
| 1989-2000 | Group head at the Bernhard-Nocht-Institute for tropical medicine Hamburg |
| 1989 | Visiting associate, Laboratory of Immunoregulation, National Institutes of Health, Bethesda, Maryland, USA |
| 1985-1988 | Postdoc, Laboratory of Immunoregulation, National Institutes of Health, Bethesda, Maryland, USA, funded by the German Academic Exchange Service (DAAD) |
| 1984 | PhD as Dr. rer. nat., University Bremen |
| 1980-1985 | Research assistant, University Bremen |
| 1980 | Diploma in biology, University Bremen |
Awards · Appointments · Scientific Activities
| Since 2009 | Member at the editorial board of molecular immunology, frontiers in innate immunity |
| 2009 | Excellence award from the Deutsche Gesellschaft für Hygiene und Mikrobiologie |
| Since 2008 | Representative of the graduate school International Leibniz Research School for Microbial and Biomolecular Interactions (ILRS) |
| 2008 | EFIS lecture award of the European Federation of Immunological Societies |
| Since 2007 | Principal investigator of the excellence graduate school Jena School for Microbial Communication (JSMC) |
| 2007 | Heinz Spitzbart award of the European Society for Infectious Diseases in Obstetrics and Gynaecology (ESIDOG) |
| Since 2006 | Principal investigator of the graduate school International Leibniz Research School for Microbial and Biomolecular Interactions (ILRS) |
| 2007-2011 | President of the European Complement Network |
| 2005 – 2012 | Board member of the European Complement Network |
| 2004 | Thuringian research award |
| Since 2002 | Deputy Director of the Leibniz-Institute for Natural Product Research and Infection Biology – Hans-Knöll-Institute Jena |
| Since 2000 | Project leader for infection biology, L2 |
| 1999-2001 | Member at the editorial board of experimental and clinical immunology, thrombosis and haemostasis, section editor molecular immunology Member of the European Working Party on the Genetics of Complement mediated Kidney Diseases, Deutsche Gesellschaft für Hygiene und Mikrobiologie (DGHM), Deutsche Gesellschaft für Immunologie, Gesellschaft für Genetik, Gesellschaft für Nephrologie |
Publications
(2019)
Author Correction: Immune evasion of Borrelia miyamotoi: CbiA, a novel outer surface protein exhibiting complement binding and inactivating properties.
Sci Rep 9(1),
7056.
(2019)
Complement 5a receptor polymorphisms are associated with PVL-positive Staphylococcus aureus colonization in African Pygmies.
Clin Infec Dis 68(5),
854-856.
(2019)
C3 glomerulopathy – Understanding a rare complement-driven renal disease.
Nat Rev Nephrol 15(3),
129-143.
(Review)
(2019)
Recombinant production of MFHR1, a novel synthetic multitarget complement inhibitor, in moss bioreactors.
Front Plant Sc 10,
260.
(2019)
Elucidating the immune evasion mechanisms of Borrelia mayonii, the causative agent of lyme disease.
Front Immunol 10,
2722.
(2019)
ApoE attenuates unresolvable inflammation by complex formation with activated C1q.
Nat Med 25(3),
496-506.
(2019)
The Case: A 78-year-old woman with acute kidney injury and hemolytic anemia.
Kidney Int 95(2),
473-474.
(2019)
C3-glomerulopathy autoantibodies mediate distinct effects on complement C3- and C5-convertases.
Front Immunol 10,
1030.
(2019)
Complement inhibitors in clinical trials for glomerular diseases.
Front Immunol 10,
2166.
(Review)
